Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
about
Ryanodine receptor-mediated arrhythmias and sudden cardiac death.Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.Levosimendan does not improve cardiac output or blood pressure in a rodent model of propranolol toxicity when administered using various dosing regimens.Levosimendan infusion improves cardiac output but not blood pressure in a rodent model of severe metoprolol toxicity.
P2860
Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Levosimendan: a novel inotropi ...... , decompensated heart failure.
@ast
Levosimendan: a novel inotropi ...... , decompensated heart failure.
@en
type
label
Levosimendan: a novel inotropi ...... , decompensated heart failure.
@ast
Levosimendan: a novel inotropi ...... , decompensated heart failure.
@en
prefLabel
Levosimendan: a novel inotropi ...... , decompensated heart failure.
@ast
Levosimendan: a novel inotropi ...... , decompensated heart failure.
@en
P2860
P356
P1476
Levosimendan: a novel inotropi ...... , decompensated heart failure.
@en
P2093
Grace L Earl
James T Fitzpatrick
P2860
P304
P356
10.1345/APH.1G128
P407
P577
2005-10-11T00:00:00Z